Join
Live feed
·
PRReleasevia Quantisnow
Emergent BioSolutions Inc. logo

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

ByQuantisnow·Wall Street's wire, on your screen.
EBS· Emergent BioSolutions Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EBS (Emergent BioSolutions Inc.) and more on Quantisnow.